Elif Şenocak Taşçı, Arda Ulaş Mutlu, Onur Saylık, Ömer Fatih Ölmez, Ahmet Bilici, Erdem Sünger, Osman Sütçüoğlu, Ömür Berna Çakmak Öksüzoğlu, Nuriye Özdemir, Orhun Akdoğan, İbrahim Vedat Bayoğlu, Nargiz Majidova, Ali Kaan Güren, Esra Özen Engin, İlhan Hacıbekiroğlu, Özlem Er, Faysal Dane, Mustafa Bozkurt, Esra Turan Canbaz, Sibel Erdamar, Erman Aytaç, Leyla Özer, İbrahim Yıldız
Total neoadjuvant therapy (TNT) has emerged as a promising approach for managing locally advanced rectal cancer (LARC), aiming to enhance resectability, increase pathological complete response (pCR), improve treatment compliance, survival, and sphincter preservation. This study compares the clinical outcomes of TNT, with either induction or consolidation chemotherapy, to those of the standard chemoradiotherapy (CRT). In this retrospective multi-institutional study, patients with stage II-III LARC who underwent CRT or TNT from seven oncology centers between 2021 and 2024 were retrospectively analyzed...
September 21, 2024: Cancers